Valneva SE announced on June 26, 2025, an exclusive agreement with CSL Seqirus for the marketing and distribution of Valneva’s three proprietary vaccines in Germany. CSL Seqirus, a major influenza vaccine company, will begin commercializing IXCHIQ® from July 2025, and IXIARO® and DUKORAL® from January 2026.
This new three-year agreement replaces Valneva's previous marketing and distribution agreement with Bavarian Nordic, which concludes at the end of December 2025. The partnership is expected to ensure seamless distribution and continued sales growth in Germany, which is Europe's largest travel vaccine market.
The agreement includes minimum annual purchasing quantities and standard termination clauses, providing a stable commercial foundation. This strategic move leverages CSL Seqirus's strong commercial presence to complement Valneva's in-house commercial infrastructure in other key European markets, supporting the company's projected product sales growth of €170-180 million in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.